198 related articles for article (PubMed ID: 17486070)
1. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Lin J; Sun T; Ji L; Deng W; Roth J; Minna J; Arlinghaus R
Oncogene; 2007 Oct; 26(49):6989-96. PubMed ID: 17486070
[TBL] [Abstract][Full Text] [Related]
2. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
3. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo.
Wang S; Wilkes MC; Leof EB; Hirschberg R
FASEB J; 2005 Jan; 19(1):1-11. PubMed ID: 15629889
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
8. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
[TBL] [Abstract][Full Text] [Related]
9. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
10. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Podtcheko A; Ohtsuru A; Tsuda S; Namba H; Saenko V; Nakashima M; Mitsutake N; Kanda S; Kurebayashi J; Yamashita S
J Clin Endocrinol Metab; 2003 Apr; 88(4):1889-96. PubMed ID: 12679488
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
[TBL] [Abstract][Full Text] [Related]
12. Abl tyrosine kinase promotes dorsal ruffles but restrains lamellipodia extension during cell spreading on fibronectin.
Jin H; Wang JY
Mol Biol Cell; 2007 Oct; 18(10):4143-54. PubMed ID: 17686996
[TBL] [Abstract][Full Text] [Related]
13. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo.
Ito I; Ji L; Tanaka F; Saito Y; Gopalan B; Branch CD; Xu K; Atkinson EN; Bekele BN; Stephens LC; Minna JD; Roth JA; Ramesh R
Cancer Gene Ther; 2004 Nov; 11(11):733-9. PubMed ID: 15486560
[TBL] [Abstract][Full Text] [Related]
14. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Liu J; Wu Y; Arlinghaus RB
Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
[TBL] [Abstract][Full Text] [Related]
15. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.
Galan-Moya EM; Hernandez-Losa J; Aceves Luquero CI; de la Cruz-Morcillo MA; Ramírez-Castillejo C; Callejas-Valera JL; Arriaga A; Aranburo AF; Ramón y Cajal S; Silvio Gutkind J; Sánchez-Prieto R
Int J Cancer; 2008 Jan; 122(2):289-97. PubMed ID: 17893873
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase.
Stephens RS; Servinsky LE; Rentsendorj O; Kolb TM; Pfeifer A; Pearse DB
Am J Physiol Cell Physiol; 2014 Mar; 306(6):C559-69. PubMed ID: 24401847
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407
[TBL] [Abstract][Full Text] [Related]
18. A myristoyl/phosphotyrosine switch regulates c-Abl.
Hantschel O; Nagar B; Guettler S; Kretzschmar J; Dorey K; Kuriyan J; Superti-Furga G
Cell; 2003 Mar; 112(6):845-57. PubMed ID: 12654250
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells.
Kondo M; Ji L; Kamibayashi C; Tomizawa Y; Randle D; Sekido Y; Yokota J; Kashuba V; Zabarovsky E; Kuzmin I; Lerman M; Roth J; Minna JD
Oncogene; 2001 Sep; 20(43):6258-62. PubMed ID: 11593436
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Dziba JM; Ain KB
J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
